Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Assets: 2021-2024

Historic Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $331.8 million.

  • Kiniksa Pharmaceuticals International's Current Assets rose 52.76% to $475.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $475.5 million, marking a year-over-year increase of 52.76%. This contributed to the annual value of $331.8 million for FY2024, which is 20.09% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Current Assets of $331.8 million as of FY2024, which was up 20.09% from $276.3 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Current Assets peaked at $331.8 million during FY2024, and registered a low of $196.4 million during FY2021.
  • Its 3-year average for Current Assets is $283.7 million, with a median of $276.3 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Current Assets shows a peak YoY grew of 23.73% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Current Assets stood at $196.4 million in 2021, then increased by 23.73% to $243.1 million in 2022, then increased by 13.67% to $276.3 million in 2023, then grew by 20.09% to $331.8 million in 2024.